


Please type a plus sign (+) inside this box → [ + ]



PTO/SB08A (08-03)

U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>SHEET 1 of 2</p>	<b>COMPLETE IF KNOWN</b>	
	Application Number	10/633,743
	Confirmation Number	5602
	Filing Date	8/04/2003
	First Named Inventor	Jeffrey Lyle Gray
	Group Art Unit	1626
	Examiner Name	Rebecca Anderson
Attorney Docket Number	9018M2	

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
RA	1	US-5,541,161	07/30/1996	Krstenansky et al.	
RA	2	US-4,530,836	07/23/1985	Yanaiharu et al.	

### FOREIGN PATENT DOCUMENTS


EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RA	3	EP 0	132919 B1		10/29/1986	Amano Pharmaceutical Co., Ltd.		
RA	4	WO 97/40017	A2		10/30/1997	Novo Nor disk A/S		
RA	5	WO 97/40017	A3		10/30/1997	Novo Nor disk A/S		
RA	6	WO 00/42213			07/20/2000	The Research Foundation of State U. of NY		
RA	7	WO 00/53583			09/14/2000	Pharmacia & Upjohn AB		
RA	8	WO 00/71101	A2		11/30/2000	Queen's U. of Kingston		
RA	9	WO 00/71101	A3		11/30/2000	Queen's U. of Kingston		
RA	10	WO 01/16097	A1		03/08/2001	Sugen, Inc.		
RA	11	WO 01/74762	A2		10/11/2001	Phycogen, Inc.		
RA	12	WO 01/74762	A3		10/11/2001	Phycogen, Inc.		
RA	13	WO 02/11722	A1		02/14/2002	Aventis Pharma Deutschland GMBH		
RA	14	WO 03/082263	A1		10/09/2003	Ontogen Corp.		
RA	15	WO 99/11606	A2		03/11/1999	Pharmacia & Upjohn Co.		
RA	16	WO 99/11606	A3		03/11/1999	Pharmacia & Upjohn Co.		
EXAMINER <i>Rebecca Anderson</i>						DATE CONSIDERED 12/15/03		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [ + ]



PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

TRADEMARK

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2

### COMPLETE IF KNOWN

Application Number	10/633,743
Confirmation Number	5602
Filing Date	8/04/2003
First Named Inventor	Jeffrey Lyle Gray
Group Art Unit	1626
Examiner Name	Rebecca Anderson
Attorney Docket Number	9018M2

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	r <sup>2</sup>
RA	17	GALAS M.C. et al., "Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity", Am. J. Physiol., 1988, Vol. 254 (2 Pt.1), pp. G176-G182.	
RA	18	TAKEDA, Y. et al., "Comparison of CCK-8 Receptors in the Pancreas and Brain of Rats Using CCK-8 Analogues", Japn. J. Pharmacol., 1989, Vol. 49, pp. 471-481.	
RA	19	CASTIGLIONE, R. "Structure-Activity Relationships in Ceruletide-like Peptides", Horm. Recept. Dig. Tract Physiol., Proc. Int. Symp., 1977, Vol. 3, pp. 33-42.	
RA	20	BLASKOVICH, M. et al., "Recent discovery and development of protein tyrosine phosphatase inhibitors", Expert Opinion on Therapeutic Patents, Ashley Publications, GB, 2002, Vol. 12, No. 6, pp. 871-905.	
EXAMINER	DATE CONSIDERED 12/15/05		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08

(Revised for P&G use 10/8/2003)